Uncategorized

Strong growth and pipeline momentum with three new medicines approved since the third quarter

PARIS, FRANCE, 8 February 2024 – Ipsen, a global specialty-care biopharmaceutical company, presents its financial results for the year and final quarter of 2023.

Kyverna Therapeutics, Inc. announced the pricing of its upsized initial public offering of 14,500,000 shares of its common stock at an initial public offering price of $22.00 per share.

Academic and industry jobs are distinguished by their approaches to collaboration and exploratory research, among other factors.

FDA backing for the Wavewriter SCS systems allows the company to challenge Abbott and Nevro.

The U.K. health assessor the National Institute of Health and Care Excellence (NICE) has issued guidance endorsing the use of Brainomix 360 (formerly known as e-Stroke) to help clinical decision making in stroke.

In comments on a proposed rule, the American Hospital Association argued regulators haven’t fully addressed how they’ll handle oversight for some situations, like when an insurer fails to pay after a dispute determination.

Lurie Children’s Hospital first reported the outage last week. Phone, email and electronic systems are still down.

The layoffs come after the CEO praised the divisions’ “momentum” on a fourth-quarter earnings call.

The insurer on Wednesday joined its peers in slamming proposed MA payment rates as insufficient given the dogged increase in medical costs.